Refractory Dissecting Cellulitis of the Scalp Treated With Risankizumab: 2 Case Reports

This document discusses two case reports of refractory dissecting cellulitis of the scalp (DCS), a rare and aggressive chronic inflammatory condition that primarily affects males and African Americans, leading to scarring alopecia and significant psychological distress. The study highlights the use of risankizumab, a medication typically used for psoriasis, as a treatment option for DCS. The cases demonstrate that risankizumab may be effective in managing symptoms and improving the quality of life for patients with this debilitating condition.